Your browser doesn't support javascript.
loading
Challenges in the development of dopamine D2- and D3-selective radiotracers for PET imaging studies.
Mach, Robert H; Luedtke, Robert R.
Affiliation
  • Mach RH; Department of Radiology, Perelman School Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Luedtke RR; Department of Pharmacology and Neuroscience, University of North Texas Health Science Center-Fort Worth, Fort Worth, TX, USA.
J Labelled Comp Radiopharm ; 61(3): 291-298, 2018 03.
Article in En | MEDLINE | ID: mdl-28857231
The dopamine D2-like receptors (ie, D2/3 receptors) have been the most extensively studied CNS receptor with Positron Emission Tomography (PET). The 3 different radiotracers that have been used in these studies are [11 C]raclopride, [18 F]fallypride, and [11 C]PHNO. Because these radiotracers have a high affinity for both dopamine D2 and D3 receptors, the density of dopamine receptors in the CNS is reported as the D2/3 binding potential, which reflects a measure of the density of both receptor subtypes. Although the development of D2- and D3-selective PET radiotracers has been an active area of research for many years, this by and large presents an unmet need in the area of translational PET imaging studies. This article discusses some of the challenges that have inhibited progress in this area of research and the current status of the development of subtype selective radiotracers for imaging D3 and D2 dopamine receptors with PET.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Dopamine D2 / Radiopharmaceuticals / Positron-Emission Tomography / Receptors, Dopamine D3 Language: En Journal: J Labelled Comp Radiopharm Year: 2018 Document type: Article Affiliation country: United States Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Dopamine D2 / Radiopharmaceuticals / Positron-Emission Tomography / Receptors, Dopamine D3 Language: En Journal: J Labelled Comp Radiopharm Year: 2018 Document type: Article Affiliation country: United States Country of publication: United kingdom